The San Francisco Bay Area has experienced a particularly intense HIV epidemic, with men who have sex with men (MSM), Black, and Latinx populations most heavily impacted in the region; and transpeople and people who inject drugs important populations for engagement. Drs. Susan Buchbinder and Diane Havlir are scientific leaders in HIV prevention and treatment, respectively. Together they will lead the San Francisco Bay Area Clinical Trials Unit (SFBay CTU), affiliated with the ACTG, HPTN, and HVTN. This integrated research organization will accomplish 3 specific aims through these Networks: 1) advance prevention and treatment science and their intersection within the Clinical Trials Networks; 2) implement clinical trials efficiently and with excellent adherence to protocol while engaging diverse communities; and 3) develop a new generation of diverse leaders in HIV prevention and treatment science. Drs. Buchbinder and Havlir are joined by a diverse pool of talented investigators who have provided leadership across the Networks, serving on numerous scientific leadership committees and working groups and chairing a range of prevention and treatment protocols. The two Clinical Research Sites, the Bridge HIV CRS (affiliated with HVTN and HPTN and led by Dr. Hyman Scott) and the UCSF CRS (affiliated with ACTG and led by Dr. Annie Leutkemeyer) have records of excellence in enrollment, retention, and adherence to protocol requirements, and actively engage local communities throughout the San Francisco Bay Area. This application represents a renewal of the SFBay CTU, with several improvements, including new leadership by an accomplished, diverse group of investigators; integration of community programs into a single, status-neutral team; expansion of community engagement and recruitment into the East and South Bays of San Francisco; and full integration of early stage investigators in all aspects of the science of the SFBay CTU. Through a smoothly running research infrastructure, divided into Scientific, Operational, and Community Engagement Steering Committees, the SFBay CTU is committed to continued leadership in the ACTG, HPTN, and HVTN, and contributing to breakthroughs in the science of HIV prevention, treatment, and cure.

Public Health Relevance

The San Francisco Bay Clinical Trials Unit will conduct HIV vaccine, prevention and treatment trials in San Francisco with a broad community engagement reach throughout the San Francisco Bay area. By bringing together leading scientists and a diverse community in the San Francisco Bay Area, this research unit will continue to develop ways to prevent and treat HIV infections and work towards an effective HIV vaccine, new pre-exposure prophylaxis agents, multipurpose prevention technologies, new TB therapies, and an HIV cure.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Coates, Cindy Karen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Public Health Foundation Enterprises
City of Industry
United States
Zip Code
Wilson, Erin C; Jalil, Emilia M; Castro, Cristiane et al. (2018) Barriers and facilitators to PrEP for transwomen in Brazil. Glob Public Health :1-9
Angelidou, Konstantia; Hunt, Peter W; Landay, Alan L et al. (2018) Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis 218:239-248
Giguere, Rebecca; Rael, Christine Tagliaferri; Sheinfil, Alan et al. (2018) Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav 22:388-401
Hughes, Shana D; Sheon, Nicolas; Andrew, Erin V W et al. (2018) Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. Med Anthropol 37:387-400
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Scheer, Susan; Hsu, Ling; Schwarcz, Sandra et al. (2018) Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the ""Getting to Zero"" Era. Clin Infect Dis 66:1027-1034
Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis 67:411-419
Fuchs, Jonathan D; Stojanovski, Kristefer; Vittinghoff, Eric et al. (2018) A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS 32:104-111
Ramsuran, Veron; Naranbhai, Vivek; Horowitz, Amir et al. (2018) Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science 359:86-90
Jalil, Emilia M; Grinsztejn, Beatriz; Velasque, Luciane et al. (2018) Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 79:445-452

Showing the most recent 10 out of 130 publications